ABSTRACT
BACKGROUND: One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome. OBJECTIVE: To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. STUDY DESIGN: In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously. RESULTS: 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups. CONCLUSION: In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19/therapy , Hospitalization/statistics & numerical data , Inpatients/statistics & numerical data , Interleukin-17/antagonists & inhibitors , SARS-CoV-2/drug effects , Aged , Antibodies, Monoclonal, Humanized/adverse effects , COVID-19/complications , COVID-19/virology , Case-Control Studies , Diarrhea/chemically induced , Dyspnea/chemically induced , Female , Humans , Inflammation/complications , Inflammation/drug therapy , Interleukin-17/immunology , Interleukin-17/metabolism , Length of Stay/statistics & numerical data , Male , Middle Aged , Pilot Projects , Respiration, Artificial , Retrospective Studies , SARS-CoV-2/physiology , Severity of Illness Index , Treatment OutcomeSubject(s)
COVID-19 , Echocardiography , Humans , Prognosis , SARS-CoV-2 , Tricuspid Valve/diagnostic imagingSubject(s)
COVID-19/complications , Edema/complications , Hand/blood supply , Pain/etiology , SARS-CoV-2 , Venous Thrombosis/complications , COVID-19/epidemiology , Edema/diagnosis , Female , Humans , Middle Aged , Pain/diagnosis , Pandemics , Thrombectomy/methods , Ultrasonography, Doppler, Color , Venous Thrombosis/diagnosis , Venous Thrombosis/surgerySubject(s)
COVID-19 , Lung Injury , Correlation of Data , Critical Illness , Humans , Lung/diagnostic imaging , Lung Injury/diagnostic imaging , SARS-CoV-2Subject(s)
COVID-19/physiopathology , Lung/diagnostic imaging , Prone Position/physiology , Respiratory Distress Syndrome/physiopathology , Adult , COVID-19/diagnostic imaging , Cohort Studies , Female , Humans , Male , Middle Aged , Patient Positioning/methods , Prospective Studies , Respiratory Distress Syndrome/diagnostic imaging , Russia , Ultrasonography/methodsABSTRACT
Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.
Subject(s)
COVID-19/complications , Heart Failure/drug therapy , Respiratory Distress Syndrome/drug therapy , SARS-CoV-2/physiology , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Acute Disease , Aged , COVID-19/virology , Heart Failure/diagnostic imaging , Heart Failure/etiology , Humans , Male , Recombinant Proteins , Respiratory Distress Syndrome/diagnostic imaging , Respiratory Distress Syndrome/etiologyABSTRACT
AIM: Noninvasive ventilation (NIV) is known to reduce intubation in patients with acute hypoxemic respiratory failure (AHRF). We aimed to assess the outcomes of NIV application in COVID-19 patients with AHRF. MATERIALS & METHODS: In this retrospective cohort study, patients with confirmed diagnosis of COVID-19 and AHRF receiving NIV in general wards were recruited from two university-affiliated hospitals. Demographic, clinical, and laboratory data were recorded at admission. The failure of NIV was defined as intubation or death during the hospital stay. RESULTS: Between April 8 and June 10, 2020, 61 patients were enrolled into the final cohort. NIV was successful in 44 out of 61 patients (72.1%), 17 patients who failed NIV therapy were intubated, and among them 15 died. Overall mortality rate was 24.6%. Patients who failed NIV were older, and had higher respiratory rate, PaCO2, D-dimer levels before NIV and higher minute ventilation and ventilatory ratio on the 1-st day of NIV. No healthcare workers were infected with SARS-CoV-2 during the study period. CONCLUSIONS: NIV is feasible in patients with COVID-19 and AHRF outside the intensive care unit, and it can be considered as a valuable option for the management of AHRF in these patients.